India, March 26 -- image credit- shutterstock

AdjuTec Pharma AS, a Norway-based startup developing antibiotic resistance breakers, has entered into a research collaboration agreement with Panchkula-basedVenus Remedies Limited. Venus Remedies Limited will perform a pre-clinical evaluation of AdjuTec Pharma's APC-148 platform technology.

AdjuTec Pharma has developed novel inhibitor technologies that selectively destroy antibiotic resistance mechanisms in multidrug-resistant bacteria, thereby restoring the effectiveness of commercially available antibiotics. APC-148 is the lead programme, that is presently in phase 1 clinical trials.

As a frontrunner in antimicrobial resistance (AMR) research, Venus Remedies Limited will leverage its adva...